| 000 | 00967 a2200265 4500 | ||
|---|---|---|---|
| 005 | 20250515153706.0 | ||
| 264 | 0 | _c20091109 | |
| 008 | 200911s 0 0 eng d | ||
| 022 | _a1996-3181 | ||
| 024 | 7 |
_a10.2174/187152708787122941 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aYan, J | |
| 245 | 0 | 0 |
_aNF-kappa B, a potential therapeutic target for the treatment of multiple sclerosis. _h[electronic resource] |
| 260 |
_bCNS & neurological disorders drug targets _cDec 2008 |
||
| 300 |
_a536-57 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aDrug Delivery Systems _xmethods |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMultiple Sclerosis _xdrug therapy |
| 650 | 0 | 4 |
_aNF-kappa B _xmetabolism |
| 700 | 1 | _aGreer, J M | |
| 773 | 0 |
_tCNS & neurological disorders drug targets _gvol. 7 _gno. 6 _gp. 536-57 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2174/187152708787122941 _zAvailable from publisher's website |
| 999 |
_c18577393 _d18577393 |
||